Vor Biopharma Inc. (VOR)
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
$64.44M
Dr. Robert Ang M.B.A., M.D., MBBS
135.00
Cambridge, MA
Feb 04, 2021
-0.54
$-1.73
2.53
15.05
0.00%
-1.15
0.58
0.00
14.70
-40.96%
-48.72%
Similar stocks (16)
Nuvalent, Inc.
NUVL
Arcellx, Inc.
ACLX
Kymera Therapeutics, Inc.
KYMR
Edgewise Therapeutics, Inc.
EWTX
Nurix Therapeutics, Inc.
NRIX
Day One Biopharmaceuticals, Inc.
DAWN
Cullinan Oncology, Inc.
CGEM
Erasca, Inc.
ERAS
Foghorn Therapeutics Inc.
FHTX
Monte Rosa Therapeutics, Inc.
GLUE
Design Therapeutics, Inc.
DSGN
Shattuck Labs, Inc.
STTK
Ventyx Biosciences, Inc.
VTYX
Adicet Bio, Inc.
ACET
Bolt Biotherapeutics, Inc.
BOLT
Lyra Therapeutics, Inc.
LYRA
ETF Exposure (12)
iShares Micro-Cap ETF
IWC
0.00982%
Dimensional U.S. Core Equity 2 ETF
DFAC
1.3e-5%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (16)
Nuvalent, Inc.
NUVL
Arcellx, Inc.
ACLX
Kymera Therapeutics, Inc.
KYMR
Edgewise Therapeutics, Inc.
EWTX
Nurix Therapeutics, Inc.
NRIX
Day One Biopharmaceuticals, Inc.
DAWN
Cullinan Oncology, Inc.
CGEM
Erasca, Inc.
ERAS
Foghorn Therapeutics Inc.
FHTX
Monte Rosa Therapeutics, Inc.
GLUE
Design Therapeutics, Inc.
DSGN
Shattuck Labs, Inc.
STTK
Ventyx Biosciences, Inc.
VTYX
Adicet Bio, Inc.
ACET
Bolt Biotherapeutics, Inc.
BOLT
Lyra Therapeutics, Inc.
LYRA
ETF Exposure (12)
iShares Micro-Cap ETF
IWC
0.00982%
Dimensional U.S. Core Equity 2 ETF
DFAC
1.3e-5%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%